This study is testing a new way to treat early-stage triple-negative breast cancer, which is a type of cancer that doesn't have three common features found in other breast cancers. The study is comparing two treatments: one with a shorter chemo-immunotherapy plan that doesn't use anthracycline drugs, and the usual plan that does. Paclitaxel and docetaxel are drugs that stop cancer cells from growing. Carboplatin is a medicine that helps kill cancer cells. Pembrolizumab helps stop tumor cells from growing by blocking certain enzymes. The study aims to see if the shorter treatment works just as well as the usual treatment.

• The study lasts up to 5 years, with check-ups every 6 months for the first 2 years.
• Participants may need to give blood samples during the study.
• The study includes regular visits and possibly receiving pembrolizumab after surgery.

Patients must have specific types of breast cancer and meet other health criteria to join. The goal is to see if the shorter treatment is as safe and effective as the usual treatment.